June 11, 2021 10:08 AM EDTUpdated 10:21 AM

Intercept retools C-suite with a pair of newcomers; Charles Ryan moves past Alzheimer's flops with another CEO challenge

Alex Hoffman

Copy Chief

Kathy Wong

Editor

→ Jason Campagna and Sandip Kapadia were two execs who punched their tickets out of Intercept as things went pear-shaped, and the teetering NASH biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Intercept retools C-suite with a pair of newcomers; Charles Ryan moves past Alzheimer's flops with another CEO challenge

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Exclusive: Florida cancer biotech raises $100M Series A

Sofinnova outlines $550M fund after IPOs and M&A deals

In­ter­cept re­tools C-suite with a pair of new­com­ers; Charles Ryan moves past Alzheimer's flops with an­oth­er CEO chal­lenge

Copy Chief

Editor

Sign up to read this article for free.

more like this

Intercept retools C-suite with a pair of newcomers; Charles Ryan moves past Alzheimer's flops with another CEO challenge